EN DE
Watch Oxford BioMedica PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Oxford BioMedica PLC (OXB) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Oxford BioMedica PLC stock £4.18, price £5.49, that is 23.9% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BDFBVT43

OB Oxford BioMedica PLC logo Thin data Nov 10, 2026

Oxford BioMedica PLC

OXB · LSE
Expensive, weak quality

Our calculation puts a fair price 24% below what the stock costs today.

Low debt
Profit last quarter +107% vs. a year ago.
Expensive Growth (revenue 5y +14.0 %/yr in GBP)
Mixed vs. peers (4/10)
Fair value £4.18 · Overvalued
Quality 32/100
Loss-making · -23.2% net margin (TTM)
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Oxford BioMedica PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£16.34 £1.67 Fair Value £4.18 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £1.67 – £16.34 · fair‑value band £3.14 – £5.23 · the £5.49 price screens above the £4.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Oxford BioMedica in your weekly email

Every Wednesday you see whether Oxford BioMedica is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Show moreShow less

Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.

The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types.

The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Stock analysis

Oxford BioMedica PLC (OXB) currently trades at £5.49, while our estimate is £4.18, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £3.14 (bear) to £5.23 (bull), the price of £5.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Oxford BioMedica PLC reported revenue of £169M in FY2025 versus £143M in FY2021, a compound +4.3%/yr. Reported net income was −£30.1M in FY2025.

Key figures

Market cap £664M Small · P/S ratio 3.67 · EPS (TTM) £−0.3200 · Net margin −23.2% · Return on equity −89.7% · Return on assets (EBIT) −19.6% (5-year average) · Operating margin −26.9% · Revenue (TTM) £175M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −24%, OXB screens richer than that median.

Fair Value

Bear £3.14 Fair Value £4.18 Bull £5.23
Price £5.49 · Downside -23.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 35
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 23
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+31.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
Start year 2020 (pandemic). Over 10 years: +26.6% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.5% (2020) → −19.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OXB screens overvalued: fair value 24% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oxford BioMedica PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −23.9% · Above median
Profitability
Return on assets −9.3% · Above median
Net margin (12 months) −23.2% · Below median
Operating margin (12 months) −26.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 9.0% · Above median
Balance sheet
Debt / equity 0.45× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.27× · Priciest 25%
P/S (12 months) 3.79× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 0
FUTURE (revenue growth)45 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)77 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs OXB
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs OXB
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs OXB
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs OXB
argenx SE ARGX $971.55 $908.40 −7% vs OXB
CSL Limited CSL A$201.68 A$181.40 −10% vs OXB
Moderna, Inc MRNA $250.83 $158.70 −37% vs OXB
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs OXB
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs OXB
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs OXB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oxford BioMedica PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Oxford BioMedica PLC Fair Value". https://www.fairvalue-calculator.com/stock/OXB

Frequently asked questions

Is Oxford BioMedica PLC (OXB) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £4.18 versus a price of £5.49, about 24% lower (overvalued).
What is the fair value of OXB?
Our estimate for Oxford BioMedica PLC is £4.18 (as of Nov 10, 2026), built from audited fundamentals. The current price: £5.49.
What is the quality score of OXB?
Oxford BioMedica PLC has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oxford BioMedica PLC (OXB)?
Our calculated price target is the estimate of £4.18 (as of Nov 10, 2026). Cautious scenario £3.14, optimistic scenario £5.23. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Oxford BioMedica PLC stock forecast for 2026?
Our estimate puts fair value at £4.18, about 24% lower versus a price of £5.49 (overvalued). Cautious scenario £3.14, optimistic scenario £5.23. The calculation is refreshed regularly with new filings.
What is the revenue of Oxford BioMedica PLC (OXB)?
Oxford BioMedica PLC reported trailing-twelve-month revenue of about £175M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Oxford BioMedica PLC (OXB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oxford BioMedica PLC it is £4.18 per share (as of Nov 10, 2026), against a price of £5.49.
Is Oxford BioMedica PLC stock overvalued or undervalued in 2026?
As of Nov 10, 2026, OXB trades above its calculated fair value: price £5.49, fair value £4.18, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OXB?
No. The price is what the market pays today (£5.49); the fair value is what the company's own numbers justify (£4.18). For Oxford BioMedica PLC the two are £1.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oxford BioMedica PLC worth?
The market values Oxford BioMedica PLC at about £664M (market capitalisation, as of Nov 10, 2026). Per share that is £5.49; our models calculate a fair value of £4.18 per share.
What do the bullish and bearish scenarios say about OXB?
Our models span a range for Oxford BioMedica PLC: cautious scenario £3.14, base £4.18, optimistic £5.23 per share (as of Nov 10, 2026, price £5.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oxford BioMedica PLC (OXB)?
Balance-sheet figures for Oxford BioMedica PLC (as of Nov 10, 2026): return on equity −89.7%, debt of 0.45 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is OXB from its 52-week high?
Oxford BioMedica PLC trades at £5.49, about 40% below its 52-week high of £9.13 and 29% above the low of £4.24 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of £4.18 is for.
Which stocks are comparable to Oxford BioMedica PLC?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oxford BioMedica PLC stock attractive at the current price?
The data as of Nov 10, 2026: price £5.49, calculated fair value £4.18 (−24%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Oxford BioMedica PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oxford BioMedica PLC (OXB)?
The closing price on Nov 10, 2026 was £5.49. Our estimate is £4.18, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oxford BioMedica PLC right now?
The price sits above even our optimistic bull case (£5.23). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Oxford BioMedica PLC

How large is the market capitalisation of Oxford BioMedica PLC (OXB)?
The market capitalisation of Oxford BioMedica PLC is £664M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oxford BioMedica PLC (OXB)?
The price-to-sales ratio of Oxford BioMedica PLC is 3.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oxford BioMedica PLC (OXB)?
Earnings per share at Oxford BioMedica PLC are £−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oxford BioMedica PLC (OXB)?
The net margin of Oxford BioMedica PLC is −23.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oxford BioMedica PLC (OXB)?
The return on equity (ROE) of Oxford BioMedica PLC is −89.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oxford BioMedica PLC (OXB)?
On an EBIT basis the return on assets of Oxford BioMedica PLC is −19.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oxford BioMedica PLC (OXB)?
The operating margin of Oxford BioMedica PLC is −26.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oxford BioMedica PLC (OXB)?
Revenue at Oxford BioMedica PLC is growing +9.0% versus a year earlier (3y avg +6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oxford BioMedica PLC (OXB)?
Earnings per share at Oxford BioMedica PLC are growing +107% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Oxford BioMedica PLC (OXB) generate?
The free cash flow of Oxford BioMedica PLC is −£10.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Oxford BioMedica PLC (OXB) carry?
The net debt of Oxford BioMedica PLC is £9.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Oxford BioMedica PLC in the live analysis

One click puts Oxford BioMedica PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.